CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,428 | -10.4% | 2,521 | +10.8% | 0.01% | -16.7% |
| Q2 2023 | $127,775 | +76.5% | 2,276 | +42.2% | 0.01% | +50.0% |
| Q1 2023 | $72,413 | +6.8% | 1,601 | -4.8% | 0.00% | +33.3% |
| Q4 2022 | $67,784 | -0.3% | 1,681 | +60.4% | 0.00% | 0.0% |
| Q3 2022 | $68,000 | -20.9% | 1,048 | -25.6% | 0.00% | 0.0% |
| Q2 2022 | $86,000 | -30.6% | 1,409 | -28.7% | 0.00% | 0.0% |
| Q1 2022 | $124,000 | -19.5% | 1,975 | +1.1% | 0.00% | -40.0% |
| Q4 2021 | $154,000 | +71.1% | 1,954 | +142.1% | 0.01% | 0.0% |
| Q3 2021 | $90,000 | -11.8% | 807 | +28.7% | 0.01% | 0.0% |
| Q2 2021 | $102,000 | – | 627 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |